Viela Bio

Product Candidates

Preclinical Candidates

We are currently studying the potential of two additional product candidates in preclinical studies.

The first candidate, VIB1116, is a monoclonal antibody (mAb) designed to decrease the number and function of antigen-presenting dendritic cells. We expect to conduct preclinical toxicology studies to enable a submission of an Investigational New Drug application to the FDA in the second half of 2020.

The second candidate is a mAb cytokine fusion protein designed to inhibit inflammatory responses. We are currently conducting preclinical efficacy studies of this candidate in animal models.

viela preclinical studies
viela preclinical studies
viela preclinical studies